Venetoclax Monotherapy Active in Acute Myelogenous Leukemia

Share this content:
In patients with acute myelogenous leukemia, the highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor venetoclax is active.
In patients with acute myelogenous leukemia, the highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor venetoclax is active.

(HealthDay News) -- In patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or untreated AML unfit for intensive chemotherapy, the highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor venetoclax is active, according to a study published in Cancer Discovery.

Marina Konopleva, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a phase II single-arm study to examine use of 800 mg daily venetoclax in patients with high-risk relapsed/refractory AML or untreated AML unfit for intensive chemotherapy.

The researchers found that the overall response rate was 19 percent, and an additional 19 percent demonstrated antileukemic activity but did not meet International Working Group criteria (partial bone marrow response and incomplete hematologic recovery).

Thirty-eight percent of patients had isocitrate dehydrogenase 1/2 mutations; one-third of these patients achieved complete response or complete response with incomplete blood count recovery. At screening, 19 percent of patients had BCL2-sensitive protein index, which was associated with time on study. BH3 profiling was consistent with on-target BCL2 inhibition, and was able to identify potential mechanisms of resistance. Nausea, diarrhea, vomiting, febrile neutropenia, and hypokalemia were common adverse events.

"Venetoclax demonstrated activity and acceptable tolerability in patients with AML and adverse features," the authors write.

RELATED: Pracinostat Granted Breakthrough Therapy Designation for AML in Elderly Patients

Several authors disclosed financial ties to pharmaceutical companies, including AbbVie and Genentech, which funded the study and are collaborating to develop Venetoclax.

Reference

  1. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discovery. 2016 Aug 12. doi: 10.1158/2159-8290.CD-16-0313. [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters